Article
Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis.
The Journal of dermatological treatment - 1 May 2017
Thijs J L, Van Der Geest B A M, Van Der Schaft J, Van Den Broek M P, Van Seggelen W O, Bruijnzeel-Koomen C A F, Hijnen D J, Van Schaik R H, De Bruin-Weller M S
Abstract excerpt
Atopic dermatitis (AD) is a very common chronic inflammatory skin disease requiring long-term treatment. Mycophenolic acid (MPA) is used off-label in treatment of patients with severe AD failing Cyclosporin A (CsA) treatment, however clinical efficacy is observed in only half of the AD patients. In blood, MPA levels are known to have a large interindividual variability. Low MPA exposure and increased enzyme...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.